Rapamune (sirolimus) is a small molecule pharmaceutical. Sirolimus was first approved as Rapamune on 1999-09-15. It has been approved in Europe to treat graft rejection and kidney transplantation. It is known to target peptidyl-prolyl cis-trans isomerase FKBP1A and peptidyl-prolyl cis-trans isomerase FKBP35.
|Indication||graft rejection, kidney transplantation|
|Drug Class||Immunosuppressives: immunosuppressant, rapamycin derivatives|